Literature DB >> 20384964

The complex interrelationships between chronic lung and liver disease: a review.

P Spagnolo1, S Zeuzem, L Richeldi, R M du Bois.   

Abstract

Lung complications may occur as a result of hepatic disease from any cause and represent a highly heterogeneous group of conditions. Early recognition of such complications may be challenging but is crucial both in forming a meaningful differential diagnosis and in avoiding severe sequelae and irreversible damage. Although a number of different pathogenetic mechanisms are likely to be involved, chronic liver dysfunction may cause pulmonary manifestations because of alterations in the production or clearance of circulating cytokines and other mediators. This is likely to be the case in hepatopulmonary syndrome, portopulmonary hypertension and primary biliary cirrhosis, although their pathogenesis remains largely speculative. Moreover, the severity of lung manifestations may or may not correspond to that of liver impairment, making disease outcome often unpredictable. Congenital and inflammatory disorders, however, may primarily affect both the liver and lung. Apart from specific diseases, a number of medications can also result in pulmonary and hepatic toxic effects. This is particularly important with cytokine therapy - used to treat viral hepatitis, among other diseases - because treatment consists of drug discontinuation, which, in turn, may cause reactivation or progression of the underlying disease that the drug was used for. This review summarizes salient diagnostic and therapeutic aspects of these often misdiagnosed conditions and highlights, based on the most recent literature, the need for early referral of such patients to centres with specific expertise in the field. In fact, a multidisciplinary approach involving pulmonologists, hepatologists and, in particularly severe cases, transplant surgeons has been already proven successful.

Entities:  

Mesh:

Year:  2010        PMID: 20384964     DOI: 10.1111/j.1365-2893.2010.01307.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  6 in total

Review 1.  Resolution of severe hepato-pulmonary syndrome following transjugular portosystemic shunt procedure.

Authors:  Michael C Wallace; Alan L James; Martin Marshall; Nickolas Kontorinis
Journal:  BMJ Case Rep       Date:  2012-06-01

Review 2.  Immunogenetics of Disease-Causing Inflammation in Sarcoidosis.

Authors:  Johan Grunewald; Paolo Spagnolo; Jan Wahlström; Anders Eklund
Journal:  Clin Rev Allergy Immunol       Date:  2015-08       Impact factor: 8.667

3.  Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 2 or 3.

Authors:  David R Nelson; Yves Benhamou; Wan-Long Chuang; Eric J Lawitz; Maribel Rodriguez-Torres; Robert Flisiak; Jens W F Rasenack; Wiesław Kryczka; Chuan-Mo Lee; Vincent G Bain; Stephen Pianko; Keyur Patel; Patrick W Cronin; Erik Pulkstenis; G Mani Subramanian; John G McHutchison
Journal:  Gastroenterology       Date:  2010-07-01       Impact factor: 22.682

4.  Determinants of elevated healthcare utilization in patients with COPD.

Authors:  Tzahit Simon-Tuval; Steven M Scharf; Nimrod Maimon; Barbara J Bernhard-Scharf; Haim Reuveni; Ariel Tarasiuk
Journal:  Respir Res       Date:  2011-01-13

5.  The ET-1-mediated carbonylation and degradation of ANXA1 induce inflammatory phenotype and proliferation of pulmonary artery smooth muscle cells in HPS.

Authors:  Jing He; Bin Yi; Yang Chen; Qing Huang; Huan Wang; Kaizhi Lu; Weiling Fu
Journal:  PLoS One       Date:  2017-04-17       Impact factor: 3.240

6.  Development of a murine model of early sepsis in diet-induced obesity.

Authors:  Momina Khan; Amanda L Patrick; Alison E Fox-Robichaud
Journal:  Biomed Res Int       Date:  2014-05-25       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.